Absci Corporation
ABSI · NASDAQ · Healthcare
$9.74
$0.07 (-0.76%) today
Market Cap
$1.67B
24h Volume
$45.9M
P/E Ratio
0.0
52w High
$11.62
52w Low
$2.30
Est. AI Revenue
100%
7-Day Sparkline (Static)
Company facts
Performance
About Absci Corporation
Absci is a drug creation company that uses generative AI to design new therapeutic antibodies from scratch. It makes money through drug creation partnerships with large pharmaceutical companies and by advancing its own pipeline of AI-designed candidates.
Its Integrated Drug Creation Platform combines generative antibody design models, a large language model for designing proteins de novo, and a wet lab validation pipeline that tests AI-designed molecules in the real world. The loop between model and lab is the core of the business.
Founded in 2011 and headquartered in Vancouver, Washington, Absci trades on the NASDAQ and employs about 562 people.
Absci Corporation in the AI buildout
Absci sits where the AI Healthcare and Foundation Models layers of the buildout meet. It trains generative models on biological data to design antibodies that have never existed, then validates them in its own wet lab. The company exists because of generative biology: its revenue comes from AI drug creation partnerships and its future depends on AI-designed drugs reaching the clinic. That all-in position earns it an AI Exposure Score of 90 out of 100.
ABSI is tracked in AI Healthcare and Foundation Models, rated Pure Play on the AI Exposure leaderboard.
By the numbers
52-week range
ABSI trades at $9.74, 80% of the way up its 52-week range of $2.30 to $11.62.
Market cap
Market capitalization is $1.67B, with an AI Exposure Score of 90 out of 100.
Next earnings
Absci Corporation is next expected to report earnings on November 16, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Absci Corporation do?
Absci uses generative AI to design new therapeutic antibodies from scratch. It earns revenue through drug creation partnerships with major pharmaceutical companies and is developing its own pipeline of AI-designed drug candidates.
How is Absci Corporation exposed to AI?
Almost completely. The company exists because of generative biology, and its thesis rests on AI-designed drugs reaching the clinic. Supercycle rates it a pure play with an AI Exposure Score of 90 out of 100.
What are Absci's main products?
The Integrated Drug Creation Platform, generative antibody design AI, a de novo protein large language model that designs proteins from scratch, and a wet lab validation pipeline that tests AI-designed molecules.
Where is Absci headquartered and who leads it?
Absci is headquartered in Vancouver, Washington, and led by CEO Carl L.G. Hansen. The company was founded in 2011, employs about 562 people, and its shares trade on the NASDAQ.
Is ABCL a pure play AI stock?
Yes by Supercycle's rating. Absci's entire business is built on generative AI drug design, which places it in the pure play tier of the AI Exposure leaderboard with a score of 90 out of 100.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.